Scholarlink

Background <p>Pancreatic cancer is among the most lethal malignancies, with limited real-world data comparing frontline chemotherapy regimens across disease stages. FOLFIRINOX and gemcitabine plus nab-paclitaxel (G + P) are standard treatments with differing toxicity profiles and outcomes. This study evaluated the comparative efficacy and safety of these regimens in metastatic, locally advanced (LAPC), and borderline resectable pancreatic cancer (BRPC).</p> Methods <p>We conducted a retrospective study of 150 patients treated between October 2019 and November 2023 at a tertiary center in India. Patients received FOLFIRINOX (n = 64) or G + P (<i>n</i> = 86) as first-line therapy. Subgroup sizes included metastatic (<i>n</i> = 89), LAPC (<i>n</i> = 34), and BRPC (<i>n</i> = 27). Outcomes assessed included progression-free survival (PFS), overall survival (OS), event-free survival (EFS), response rates, resectability, and toxicities. Kaplan–Meier analysis and Cox regression were used. Subgroup analyses were stratified by stage and CA 19–9 levels.</p> Results <p>In metastatic disease, median OS was 11&#xa0;months (FOLFIRINOX) vs. 10&#xa0;months (G + P; HR = 1.26, <i>p</i> = 0.38); PFS was 6&#xa0;months in both groups. In LAPC, OS was 15.5 vs. 17&#xa0;months (<i>p</i> = 0.84). In BRPC, FOLFIRINOX showed superior OS (37 vs. 16&#xa0;months; <i>p</i> = 0.02) and higher surgical conversion (66% vs. 39%). Grade ≥ 3 toxicities occurred in 45% (FOLFIRINOX) vs. 21% (G + P). Elevated CA 19–9 (&gt; 37 U/mL) independently predicted worse OS (HR = 1.72; <i>p</i> = 0.029).</p> Conclusion <p>FOLFIRINOX and G + P have comparable efficacy in metastatic and locally advanced pancreatic cancer. FOLFIRINOX offers a survival benefit in BRPC but with higher toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety

  • 期刊论文

  • 发表日期：

    2025年8月16日

查看全文
  • Arif Mohammed Khan,
  • Vamshi Krishna Muddu,
  • Naga Avinash Bonda,
  • Indraja Siripurapu,
  • Rimsha Ahmed,
  • Safa Takreem,
  • Syeda Sana Shahnoor,
  • Sobia Noor,
  • Sannapaneni Krishnaiah,
  • G. V. Rao,
  • D. Nageshwar Reddy

摘要

Background

Pancreatic cancer is among the most lethal malignancies, with limited real-world data comparing frontline chemotherapy regimens across disease stages. FOLFIRINOX and gemcitabine plus nab-paclitaxel (G + P) are standard treatments with differing toxicity profiles and outcomes. This study evaluated the comparative efficacy and safety of these regimens in metastatic, locally advanced (LAPC), and borderline resectable pancreatic cancer (BRPC).

Methods

We conducted a retrospective study of 150 patients treated between October 2019 and November 2023 at a tertiary center in India. Patients received FOLFIRINOX (n = 64) or G + P (n = 86) as first-line therapy. Subgroup sizes included metastatic (n = 89), LAPC (n = 34), and BRPC (n = 27). Outcomes assessed included progression-free survival (PFS), overall survival (OS), event-free survival (EFS), response rates, resectability, and toxicities. Kaplan–Meier analysis and Cox regression were used. Subgroup analyses were stratified by stage and CA 19–9 levels.

Results

In metastatic disease, median OS was 11 months (FOLFIRINOX) vs. 10 months (G + P; HR = 1.26, p = 0.38); PFS was 6 months in both groups. In LAPC, OS was 15.5 vs. 17 months (p = 0.84). In BRPC, FOLFIRINOX showed superior OS (37 vs. 16 months; p = 0.02) and higher surgical conversion (66% vs. 39%). Grade ≥ 3 toxicities occurred in 45% (FOLFIRINOX) vs. 21% (G + P). Elevated CA 19–9 (> 37 U/mL) independently predicted worse OS (HR = 1.72; p = 0.029).

Conclusion

FOLFIRINOX and G + P have comparable efficacy in metastatic and locally advanced pancreatic cancer. FOLFIRINOX offers a survival benefit in BRPC but with higher toxicity.